Tesaro azioni Tumble dopo dati risultati deludenti

Jesus wishes shares Tumble after disappointing data | BenzingaBenzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn RSS Streaming Google + News free subscription is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: leave blank: you already have an account?LoginI user bet that I can't wait to come back here ... Username or email: Password: need an account?Forgot your password? Help Register Login Benzinga-Feed Your Mind. HomeMeglio of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/& FDAMarketsPre-HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong MarketAfter IdeasShort PressJim CramerRumorsETFsTechStart IdeasTechnicalsFrom UpsSmall-CapTrading-& training strategiesColorDowngradesUpgradesInitiationsPrice Target market analyst overview keyword TickersArticlesKeywordsSearch ... Jesus wishes googlecse shares Tumble after disappointing results data Erika Janowicz, Benzinga staff writer December 23, 2013 13:24 + Follow Print Email free Streaming News ticker: TSRO share:Jesus wishes shares (NASDAQ: TSRO) fell 32.19% to $28,52 as following the announcement that data from two studies have shown that rolapitant for chemotherapy-induced nausea and vomiting (CINV) missed secondary endpoints.BMO Capital Markets analyst Jim Birchenough said that investors were expecting rolapitant of Jesus wishes to differentiate itself from other treatments for CINV based on benefit of nausea that does not reach statistical significance. Birchenough added that a dosing schedule better and the absence of reactions may not be enough to differentiate from Merck Emend.Jesus wishes closed at $37,70 Friday.-Published In: BMO Capital markets Analyst Jim BirchenoughAnalyst color reviews(c) Benzinga.com 2013. Benzinga does not provide investment advice. All rights reserved.Most popular Office Depot, Seattle Genetics and other insiders have been buying Slideshow: No iPhone for China Mobile, iPad demand remains high, and more from the third week of December, China Mobile, Apple iPhone announce on China Mobile 3 G & 4 g networks beginning January 17, 2014 stock watch for December 23, 2013 UPDATE: Morgan Stanley reiterates on Walgreen company updated the following forecast 1QFY14 results Cowen suggests truth of Allergan Rumors related articles (TSRO) Jesus wishes shares Tumble after disappointing results Update Data mid-morning market: markets Surge; Seagate to acquire Xyratex for Rolapitant of $ 374 M morning market losers JESUS WISHES to reach the primary Endpoint in each of two phase 3 studies for the prevention of CINV across the Web, we're loving ... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading techniques to the new market Environment Pope Francis Rips ' trickle-down ' economics come see how the Pro trade in this exclusive Webinar, MGM, Wynn Casino Giants vying for u.s. Turf what should you know about AMZN? Network of partners get Benzinga news delivered free Zing Talk: Daily Top stories Premarket Primer see more» ETF weekly Outlook Outlook options daily weekly reviews by Erika Summary United therapeutic shares Janowicz surge higher after FDA approval of Orenitram, JP Morgan Upgrade Baird Fortinet newly appointed CFO upgrades and revenue catalysts J.P. Morgan initiates coverage on Nasdaq OMX Stifel raises PT Apple following China Mobile support Cowen suggests truth to rumors Allergan more Read more recent Office Depot 1, Seattle Genetics and other insiders have been buying 2 Slideshow: No iPhone for China Mobile, iPad demand remains high, ... 3 China Mobile, Apple iPhone announce on China Mobile 4 g 3 g NET & ... 4 stock UPDATE clock for 5 December 23, 2013: Morgan Stanley reiterates on Walgreen company on updated ... 6 Cowen suggests the truth to 7 voices Allergan iPhone finally arrives to China Mobile 1 analysts: China Mobile deal Apple will add 17 m to 30 m In Increments ... WidePoint subsidiary iSYS assigned 2 $ 600 M purchase blanket Agreeme ... 3 Jos. A banks turn down acquisition offers from men's Wearhouse 4 Corvex, comment on Commonwealth REIT related recent misleading ... 5 ETFS Facebook and Twitter Social Media power (SOCL FB TWTR SELF, GOOG ... 6 Signs pointing to another Santa Claus Rally in 2013 United therapeutic shares soaring 7 over after FDA approval. Benzinga Professional Subscribe WidePoint subsidiary iSYS 13:16 awarded contract for the purchase of $ 600 M covered by Department of Homeland Security 13:15 actions of Steiner Leisure to session highs; Stifel previous analyst suggested buying the Dip 13:12 Charles Gasparino: ' Tweet ackman says regs closing in $HLF is based on discussions w regs believe theyre making it difficult to foresee substantial progress times ' 13:10 S P & updates Philadelphia to says Boulder makes a + 13: 6 Moody Evol acquisition credit metrics Weakens in the short term 13: 2 Hercules Offshore more elevatiPuò spikes be attributed to positive comments to CNBC 13: 0 trust in Read continues as the Senate passes the motion of 2014 budget via ForexLive 12:54 update: IDC 2017 cuts Monitor PC shipment forecast from 110.8 109.6 M M 12:53 unit upgrade: enhanced 2013 IDC Monitor PC shipment forecast from 134.7 M M 12:51 136.3 says Callon consider Lone Star tips 12:50 IDC says worldwide PC Monitor will see positive growth in Q3 13Vede shipments up to 4.5% QoQ 12:49 CMS Reporting deadline for affordable care Act extended to midnight on December 24, 12: 42 adversity Adam Button shows still has some British colonial spirit within via ForexLive & 12:38 pm Gabelli co. Upgrades Stratasys, Inc. to buy DSP Group 12:28 pm Spikes higher; Can be attributed to article Benzinga Globes is a fast growing, dynamic and innovative financial media that empowers investors with high-quality content, unique. Popular BossETFsEconomicsForexHotNewsOptionsPress ChannelsAnalyst RatingsBe your ReleasesStart upsTechTools ProgramBadgesFeedsNews WidgetReal time FeaturesAffiliate & FeedSitemapSubmit TipsAbout BenzingaAbout news UsBlogIn the UsDisclaimerPrivacy and conditions PolicySyndicationTerms NewsCareersContact Benzinga partner 1 (ZING) (877) 440-9464 Benzinga.com © SFX 2013 Announces New Partnership with Anheuser-Busch InBev of Marketing